Newsroom

  • September 14, 2017
    SCIENTISTS SEE PROGRESS FOR CANCER VACCINES

    Tumor-destroying vaccines have emerged as a new weapon in the fight against cancer. Conventional vaccines prevent people from getting sick in the first place. Now scientists are testing a new type of vaccine that treats existing cancers by spurring immune cells to go on the attack. These drugs—known as therapeutic vaccines—hold the potential to plunge […]

    Learn More
  • May 16, 2017
    2017 NEVYS NOMINEE SPOTLIGHT

    Oncorus: Going Viral To Beat Cancer This week’s “2017 NEVYs Nominee Spotlight” is on Oncorus, a nominee for Hottest Early Stage Startup — Therapeutics. Today we’ll delve into why their work is so impactful to this region, and patients everywhere. Germinating an idea The approval in 2015 of Amgen’s IMLYGIC® (talimogene herparvovec), or T-VEC, established a clear regulatory […]

    Learn More
  • February 9, 2017
    THE NEXT GENERATION: TOP 20 LIFE SCIENCE STARTUPS TO WATCH IN 2017

    BioSpace (DHX) is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014. To come up with this Top 20, BioSpace sorted companies into that age grouping, and they were then weighted by a number of different categories and finally ranked in a cumulative […]

    Learn More
  • December 30, 2016
    FOUR CANCER-KILLING VIRUSES TO WATCH IN 2017

    Cancer-killing viruses are specially engineered versions of naturally occurring viruses that are programmed to home in on cancer cells and kill them without harming normal tissues. This is a branch of immuno-oncology that has been overshadowed by more fruitful endeavors, such as the immune checkpoint inhibitors Opdivo (nivolumab) from Bristol-Myers Squibb and Keytruda (pembrolizumab) from Merck, both of […]

    Learn More
  • December 15, 2016
    Oncorus, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC

    FOR IMMEDIATE RELEASE  – Proceeds Will Advance Company’s Next-Generation Platform Using Oncolytic Virus in Brain Tumors and Other Cancers –    Cambridge, MA, December 15, 2016 – Oncorus, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma […]

    Learn More
  • September 19, 2016
    FierceBiotech Names Oncorus as a “Fierce 15” Biotech Company of 2016

    The scoop: This startup is pinpointing next-gen oncolytic viruses, which could offer a less expensive, more efficacious immuno-oncology option than cellular therapy, such as autologous CAR-Ts in development. It’s going straight for the hardest-to-treat solid cancers, including a type of brain cancer, glioblastoma multiforme (GBM). Read the article from FierceBiotech.

    Learn More

Media Inquiries: media@oncorus.com

Top